News

Newron announces initiation of new clinical trial with Evenamide in patients with schizophrenia, following approval of plan by FDA

Milan, Italy and Morristown, NJ, USA, January 9, 2020 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of

Newron Pharmaceuticals to Request Type A FDA Meeting Prior to Unblinding of STARS Clinical Trial Data

Meeting expected to occur within thirty days of FDA’s receipt of the meeting request and meeting package STARS (Sarizotan Treatment of Apneas in Rett Syndrome) clinical study to

Newron Receives Second Tranche from Financing Agreement with European Investment Bank (EIB)

Milan, Italy – November 25, 2019 - Newron Pharmaceutical S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for

Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome

Milan, Italy and Morristown, NJ, USA, November 19, 2019 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development

Newron Initiates Outreach on First Global Rett Syndrome Burden of Illness Survey in Collaboration with the Rett Community

Sponsoring the largest, most comprehensive qualitative study ever to examine the burden of Rett syndrome on individuals and their caregivers Survey outreach to begin in the United

Newron Pharmaceuticals: Commercialization partner Meiji Seika together with Eisai announce the approval of safinamide for Parkinson’s disease in Japan

Milan, Italy, September 20, 2019 – Newron Pharmaceuticals S.pA. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with

Newron reports half-year 2019 results

Milan, Italy – September 12, 2019 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients

Newron’s commercialization partner Zambon and Valeo Pharma announce the launch of Onstryv® (safinamide) for Parkinson’s disease in Canada

Milan, Italy and Montreal, Quebec – July 10, 2019 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5.XE), a biopharmaceutical company focused on the development of

Newron Receives First Tranche from Financing Agreement with European Investment Bank (EIB)

Guidance reiterated Milan, Italy – June 28, 2019 - Newron Pharmaceutical S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies

Newron Pharmaceuticals now also listed on the primary market of the Düsseldorf Stock Exchange and on XETRA

ODDO SEYDLER BANK AG acts as Capital Market Partner of the Düsseldorf Stock Exchange and Designated Sponsor Milan, Italy – June 27, 2019 – Shares of Newron Pharmaceuticals S.p.A